Sun Pharmaceutical Industries Share Price
Sector: Biotechnology & Drugs
1532.85 +1.30 (0.08%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1523.35
Today’s High
1540.85
52 Week Low
922.55
52 Week High
1638.7
1534.00 +2.60 (0.17%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1523.35
Today’s High
1538.7
52 Week Low
922.45
52 Week High
1638.85
Key Metrics
- Market Cap (In Cr) 368609.8
- Beta 0.72
- Div. Yield (%) 0.81
- P/B 6.58
- TTM P/E 33.94
- Peg Ratio 1.63
- Sector P/E 31.48
- D/E -
- Open Price 1540.85
- Prev Close 1531.55
Sun Pharmaceutical Industries Analysis
Price Analysis
-
1 Week2.79%
-
3 Months1.75%
-
6 Month29.15%
-
YTD21.98%
-
1 Year64.14%
Risk Meter
- 20% Low risk
- 20% Moderate risk
- 20% Balanced Risk
- 20% High risk
- 20% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 13
- 13
- 14
- 15
- Buy
- 11
- 11
- 11
- 12
- Hold
- 5
- 5
- 5
- 5
- Sell
- 1
- 1
- 1
- 1
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 30
- 30
- 31
- 33
Sun Pharmaceutical Industries News
Sun Pharma: 2 key reasons why HSBC expects 16% upside despite regulatory woes
2 min read . 15 Apr 2024Mahindra & Mahindra, Sun Pharmaceutical Industries & others hit 52 week high today ; Do you own any?
3 min read . 05 Apr 2024Sun Pharmaceutical Industries Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2023
- Total Revenue
- 43885.68
- Selling/ General/ Admin Expenses Total
- 19394.87
- Depreciation/ Amortization
- 2529.43
- Other Operating Expenses Total
- 738.24
- Total Operating Expense
- 34793.33
- Operating Income
- 9092.35
- Net Income Before Taxes
- 9408.43
- Net Income
- 8473.58
- Diluted Normalized EPS
- 36.01
- Period
- 2023
- Total Assets
- 80743.59
- Total Liabilities
- 24748.21
- Total Equity
- 55995.38
- Tangible Book Valueper Share Common Eq
- 158.19
- Period
- 2023
- Cashfrom Operating Activities
- 5526.02
- Cashfrom Investing Activities
- -7943.68
- Cashfrom Financing Activities
- 2376.07
- Net Changein Cash
- 115.48
- Period
- 2022
- Total Revenue
- 38654.49
- Selling/ General/ Admin Expenses Total
- 15945.42
- Depreciation/ Amortization
- 2143.74
- Other Operating Expenses Total
- 709.74
- Total Operating Expense
- 35076.82
- Operating Income
- 3577.67
- Net Income Before Taxes
- 4481.32
- Net Income
- 3272.73
- Diluted Normalized EPS
- 28.03
- Period
- 2022
- Total Assets
- 69807.77
- Total Liabilities
- 21796.55
- Total Equity
- 48011.22
- Tangible Book Valueper Share Common Eq
- 146.82
- Period
- 2022
- Cashfrom Operating Activities
- 9025.99
- Cashfrom Investing Activities
- -5724.74
- Cashfrom Financing Activities
- -5193.46
- Net Changein Cash
- -1764.78
- Period
- 2021
- Total Revenue
- 33498.14
- Selling/ General/ Admin Expenses Total
- 14344.76
- Depreciation/ Amortization
- 2079.95
- Other Operating Expenses Total
- 734.39
- Total Operating Expense
- 31351.52
- Operating Income
- 2146.62
- Net Income Before Taxes
- 2799.37
- Net Income
- 2903.82
- Diluted Normalized EPS
- 26.71
- Period
- 2021
- Total Assets
- 67666.73
- Total Liabilities
- 21203.95
- Total Equity
- 46462.78
- Tangible Book Valueper Share Common Eq
- 143.85
- Period
- 2021
- Cashfrom Operating Activities
- 6170.37
- Cashfrom Investing Activities
- 536.22
- Cashfrom Financing Activities
- -5980.48
- Net Changein Cash
- 596.42
- Period
- 2020
- Total Revenue
- 32837.5
- Selling/ General/ Admin Expenses Total
- 14593.92
- Depreciation/ Amortization
- 2052.78
- Other Operating Expenses Total
- 771.72
- Total Operating Expense
- 28129.12
- Operating Income
- 4708.38
- Net Income Before Taxes
- 5009.59
- Net Income
- 3764.93
- Diluted Normalized EPS
- 16.54
- Period
- 2020
- Total Assets
- 68252.46
- Total Liabilities
- 22988.01
- Total Equity
- 45264.45
- Tangible Book Valueper Share Common Eq
- 135.14
- Period
- 2020
- Cashfrom Operating Activities
- 6554.77
- Cashfrom Investing Activities
- -2588.84
- Cashfrom Financing Activities
- -5715.14
- Net Changein Cash
- -1385.69
- Period
- 2019
- Total Revenue
- 29065.91
- Selling/ General/ Admin Expenses Total
- 12429.44
- Depreciation/ Amortization
- 1753.25
- Other Operating Expenses Total
- 741.09
- Total Operating Expense
- 25378.21
- Operating Income
- 3687.7
- Net Income Before Taxes
- 3810.2
- Net Income
- 2665.42
- Diluted Normalized EPS
- 15.61
- Period
- 2019
- Total Assets
- 64693.81
- Total Liabilities
- 23284.75
- Total Equity
- 41409.06
- Tangible Book Valueper Share Common Eq
- 121.28
- Period
- 2019
- Cashfrom Operating Activities
- 2241.97
- Cashfrom Investing Activities
- -681.25
- Cashfrom Financing Activities
- -2730.52
- Net Changein Cash
- -844.15
- Period
- 2018
- Total Revenue
- 26489.46
- Selling/ General/ Admin Expenses Total
- 11125.37
- Depreciation/ Amortization
- 1499.84
- Other Operating Expenses Total
- 700.9
- Total Operating Expense
- 23106.4
- Operating Income
- 3383.06
- Net Income Before Taxes
- 3478.98
- Net Income
- 2095.7
- Diluted Normalized EPS
- 12.84
- Period
- 2018
- Total Assets
- 64516.35
- Total Liabilities
- 26202.24
- Total Equity
- 38314.11
- Tangible Book Valueper Share Common Eq
- 114.99
- Period
- 2018
- Cashfrom Operating Activities
- 4026.88
- Cashfrom Investing Activities
- -3370.81
- Cashfrom Financing Activities
- -1539.26
- Net Changein Cash
- -735.91
- Period
- 2023-12-31
- Total Revenue
- 12380.7
- Selling/ General/ Admin Expenses Total
- 2363.32
- Depreciation/ Amortization
- 622.14
- Other Operating Expenses Total
- 3928.17
- Total Operating Expense
- 9720.38
- Operating Income
- 2660.32
- Net Income Before Taxes
- 3000.35
- Net Income
- 2523.75
- Diluted Normalized EPS
- 10.75
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 12192.41
- Selling/ General/ Admin Expenses Total
- 2364.36
- Depreciation/ Amortization
- 632.82
- Other Operating Expenses Total
- 3827.49
- Total Operating Expense
- 9611.76
- Operating Income
- 2580.65
- Net Income Before Taxes
- 2790.88
- Net Income
- 2375.51
- Diluted Normalized EPS
- 9.9
- Period
- 2023-09-30
- Total Assets
- 79441.16
- Total Liabilities
- 19615.52
- Total Equity
- 59825.64
- Tangible Book Valueper Share Common Eq
- 175.19
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 5719.95
- Cashfrom Investing Activities
- 993.7
- Cashfrom Financing Activities
- -5876.8
- Net Changein Cash
- 779.37
- Period
- 2023-06-30
- Total Revenue
- 11940.84
- Selling/ General/ Admin Expenses Total
- 2402.04
- Depreciation/ Amortization
- 651.32
- Other Operating Expenses Total
- 3450.9
- Total Operating Expense
- 9585.3
- Operating Income
- 2355.54
- Net Income Before Taxes
- 2481.14
- Net Income
- 2022.54
- Diluted Normalized EPS
- 9.49
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 10930.67
- Selling/ General/ Admin Expenses Total
- 2179.55
- Depreciation/ Amortization
- 671.53
- Other Operating Expenses Total
- 3671.6
- Total Operating Expense
- 8944.35
- Operating Income
- 1986.32
- Net Income Before Taxes
- 2239.69
- Net Income
- 1984.47
- Diluted Normalized EPS
- 8.96
- Period
- 2023-03-31
- Total Assets
- 80743.59
- Total Liabilities
- 24748.21
- Total Equity
- 55995.38
- Tangible Book Valueper Share Common Eq
- 158.19
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 5526.02
- Cashfrom Investing Activities
- -7943.68
- Cashfrom Financing Activities
- 2376.07
- Net Changein Cash
- 115.48
- Period
- 2022-12-31
- Total Revenue
- 11240.97
- Selling/ General/ Admin Expenses Total
- 2037.07
- Depreciation/ Amortization
- 659.95
- Other Operating Expenses Total
- 3393.38
- Total Operating Expense
- 8894.07
- Operating Income
- 2346.9
- Net Income Before Taxes
- 2471.47
- Net Income
- 2166.01
- Diluted Normalized EPS
- 9
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Sun Pharmaceutical Industries Technical
Moving Average
SMA
- 5 Day1533.16
- 10 Day1523.18
- 20 Day1521.33
- 50 Day1560.59
- 100 Day1470.16
- 300 Day1311.85
Sun Pharmaceutical Industries Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Sun Pharmaceutical Industries
- 1532.85
- 1.3
- 0.08
- 1638.7
- 922.55
- 367782.06
- Cipla
- 1403.9
- 4.55
- 0.33
- 1519
- 897.7
- 113350.18
- Divis Laboratories
- 3918.75
- 6.85
- 0.18
- 4104
- 3050.15
- 104030.5
- Zydus Lifesciences
- 1104.45
- 52.55
- 5
- 1104.45
- 482.55
- 111792.89
- Dr Reddys Laboratories
- 5812.5
- 13.25
- 0.23
- 6505.5
- 4383.4
- 96794.68
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Sun Pharmaceutical Industries
- 42.42
- 6.54
- 9.23
- 12.17
- Cipla
- 26.66
- 4.25
- 13.5
- 12.66
- Divis Laboratories
- 56.65
- 8.09
- 21.28
- 27.9
- Zydus Lifesciences
- 41.92
- 5.76
- 14.77
- 12.89
- Dr Reddys Laboratories
- 17.94
- 3.46
- 16.73
- 14.63
Sun Pharmaceutical Industries Shareholding
Shareholding Pattern
*Promoter pledging: 1.12%
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 22-May-24
- Audited Results & Final Dividend
- 31-Jan-24
- Quarterly Results & Interim Dividend
- 01-Nov-23
- Quarterly Results
- 03-Aug-23
- Quarterly Results
- 26-May-23
- Audited Results & Final Dividend
- 31-Jan-23
- Quarterly Results & Interim Dividend
- 01-Nov-22
- Quarterly Results
- 29-Jul-22
- Quarterly Results
- 30-May-22
- Audited Results & Final Dividend
- 31-Jan-22
- Quarterly Results & Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 28-Aug-23
- 07-Jul-23
- AGM
- 29-Aug-22
- 03-Aug-22
- AGM
- 31-Aug-21
- 04-Aug-21
- AGM
- 16-Mar-21
- 05-Feb-21
- COM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 15-Jan-24
- 09-Feb-24
- 09-Feb-24
- 8.5
- 07-Jul-23
- 28-Jul-23
- 28-Jul-23
- 4
- 16-Jan-23
- 08-Feb-23
- 08-Feb-23
- 7.5
- 31-May-22
- -
- -
- 3
- 31-Jan-22
- 10-Feb-22
- 09-Feb-22
- 7
- 27-May-21
- -
- 23-Aug-21
- 2
- 29-Jan-21
- 10-Feb-21
- 09-Feb-21
- 5.5
![No data](https://www.livemint.com/lm-img/dev/null-data.png)
![No data](https://www.livemint.com/lm-img/dev/null-data.png)
![No data](https://www.livemint.com/lm-img/dev/null-data.png)